Biorestorative Therapies, Inc. (BRTX) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - Biorestorative Therapies, Inc. (BRTX) reported a quarterly loss of $0.38 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.13 per share a year ago [1] - The company posted revenues of $0.01 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 97%, and down from $0.23 million year-over-year [2] - Biorestorative Therapies shares have declined approximately 1.4% year-to-date, while the S&P 500 has gained 16.4% [3] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [1] - The current consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $0.5 million, and for the current fiscal year, it is -$1.55 on revenues of $1.23 million [7] Market Outlook - The earnings outlook and estimate revisions will significantly influence the stock's price movement [4] - The Zacks Rank for Biorestorative Therapies is currently 3 (Hold), indicating expected performance in line with the market [6] - The Medical - Biomedical and Genetics industry is ranked in the top 34% of over 250 Zacks industries, suggesting a favorable industry outlook [8]